Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAVEEN KUMAR TUMULA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447402896
CMS profile
746364
Location
AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,168.66

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $561.47 24
Consulting Fee $500.00 2
Education $107.19 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAVEEN KUMAR TUMULA

NPI 1447402896 · CMS profile ID 746364

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447402896?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $1,168.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $13.7311/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684185893 CMS
E.R. Squibb & Sons, L.L.C. $5.1411/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387417 CMS
E.R. Squibb & Sons, L.L.C. $250.0011/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387419 CMS
Seattle Genetics, Inc. $12.2110/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678807669 CMS
Kite Pharma, Inc. $13.6710/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662138541 CMS
Celgene Corporation $20.6909/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672928045 CMS
Clovis Oncology, Inc. $7.2009/18/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688684447 CMS
Incyte Corporation $11.8409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666278771 CMS
Merck Sharp & Dohme Corporation $65.7309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695746359 CMS
Incyte Corporation $13.3208/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666278765 CMS
TESARO, Inc. $11.3607/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675571281 CMS
Takeda Pharmaceuticals U.S.A., Inc. $125.0007/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697395577 CMS
Genentech USA, Inc. $16.2305/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681278233 CMS
Seattle Genetics, Inc. $72.3305/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678807659 CMS
TESARO, Inc. $14.6605/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675571279 CMS
Astellas Pharma US Inc $99.9905/02/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655784729 CMS
E.R. Squibb & Sons, L.L.C. $250.0004/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387429 CMS
Janssen Pharmaceuticals, Inc $15.2904/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659349041 CMS
E.R. Squibb & Sons, L.L.C. $11.5904/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387365 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.4303/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696702587 CMS
E.R. Squibb & Sons, L.L.C. $9.1502/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387369 CMS
AbbVie, Inc. $18.9602/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648247317 CMS
Astellas Pharma US Inc $12.5802/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655784725 CMS
Janssen Scientific Affairs, LLC $37.1201/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657610129 CMS
Merck Sharp & Dohme Corporation $20.7401/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695651798 CMS
PFIZER INC. $11.1001/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671856639 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.6201/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697381769 CMS
E.R. Squibb & Sons, L.L.C. $3.9801/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651387367 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,168.66 28
PY2020 $4,815.65 8
PY2021 $340.16 6
PY2022 $1,916.32 26
PY2023 $4,540.57 16
PY2024 $2,679.61 6
PY2025 $6,258.84 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,557.82 36
PY2024 Principal investigator $1,085,444.24 161
PY2023 Principal investigator $684,815.25 77
PY2022 Principal investigator $638,195.90 127
PY2021 Principal investigator $416,830.90 164
PY2020 Principal investigator $201,522.62 122
PY2019 Recipient $1,287.72 1
PY2019 Principal investigator $54,363.67 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeiGene, Ltd. $155.00 12/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933752981
Principal investigator 1 BeiGene, Ltd. $1,014.00 12/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933752987
Principal investigator 1 BeiGene, Ltd. $325.00 12/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933752991
Principal investigator 1 BeiGene, Ltd. $347.00 12/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933752993
Principal investigator 1 Incyte Corporation $120.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231955
Principal investigator 1 Incyte Corporation $1,000.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231959
Principal investigator 1 BeiGene, Ltd. $50,478.00 11/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933753063
Principal investigator 1 BeiGene, Ltd. $523.00 11/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933753285
Principal investigator 1 Genentech, Inc. $3,000.00 10/28/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
CLL 1L FIT GV FCR BR No dispute reported 06/30/2026 950640689
Principal investigator 1 Genentech, Inc. $1,500.00 10/21/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
CLL 1L FIT GV FCR BR No dispute reported 06/30/2026 950641287
Principal investigator 1 BeiGene, Ltd. $956.00 10/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933753021
Principal investigator 1 Genentech, Inc. $3,506.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
MORNINGSUN No dispute reported 06/30/2026 950692331
Principal investigator 1 Incyte Corporation $850.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231961
Principal investigator 1 Incyte Corporation $105.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231963
Principal investigator 1 Seagen Inc. $956.00 10/15/2022 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917930913
Principal investigator 1 Celgene Corporation $238.00 09/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185169
Principal investigator 1 Novartis Pharmaceuticals Corporation $586.12 09/09/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY EL PASO CANCER TREATMENT CENTER GATEWAY
A PHASE III, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF ORAL ASCIMINIB VERSUS INVESTIGATOR SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE No dispute reported 06/30/2026 909420383
Principal investigator 1 BeiGene, Ltd. $40,382.40 08/24/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933753383
Principal investigator 1 Incyte Corporation $1,000.00 07/21/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231925
Principal investigator 1 BeiGene, Ltd. $10,095.60 07/18/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933753243
Principal investigator 1 Incyte Corporation $850.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231949
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL???: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 890237403
Principal investigator 1 Seagen Inc. $956.00 07/15/2022 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917930795
Principal investigator 1 Genentech, Inc. $10,200.00 06/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
MOSUN No dispute reported 06/30/2026 950729361
Principal investigator 1 BeiGene, Ltd. $40,382.40 06/01/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933752959
Principal investigator 1 Incyte Corporation $120.00 05/19/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231795
Principal investigator 1 Incyte Corporation $1,721.67 05/05/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231811
Principal investigator 1 Incyte Corporation $360.00 05/05/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231813
Principal investigator 1 Incyte Corporation $120.00 05/05/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231817
Principal investigator 1 Incyte Corporation $106.00 05/05/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231819
Principal investigator 1 BeiGene, Ltd. $10,095.60 04/25/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933752947
Principal investigator 1 Celgene Corporation $238.00 04/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185171
Principal investigator 1 Incyte Corporation $489.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231733
Principal investigator 1 Incyte Corporation $105.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231747
Principal investigator 1 Incyte Corporation $850.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231749
Principal investigator 1 Incyte Corporation $489.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231759
Principal investigator 1 Incyte Corporation $489.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231761
Principal investigator 1 Incyte Corporation $489.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231853
Principal investigator 1 Incyte Corporation $105.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231857
Principal investigator 1 Incyte Corporation $489.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231863
Principal investigator 1 Incyte Corporation $489.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231879
Principal investigator 1 Incyte Corporation $489.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231883
Principal investigator 1 Incyte Corporation $105.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231891
Principal investigator 1 Incyte Corporation $105.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231899
Principal investigator 1 Incyte Corporation $105.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231907
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL???: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 890236529
Principal investigator 1 Seagen Inc. $956.00 04/15/2022 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917930709
Principal investigator 3 Celgene Corporation $5,630.00 04/13/2022 Non-covered Recipient Entity
Texas Oncology
Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry: The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and tr No dispute reported 06/30/2026 937185235
Principal investigator 1 Incyte Corporation $120.00 04/07/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231621
Principal investigator 1 Incyte Corporation $1,147.78 04/07/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231623
Principal investigator 1 Incyte Corporation $480.00 03/24/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231617
Principal investigator 1 Celgene Corporation $714.00 03/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185225
Principal investigator 1 Incyte Corporation $105.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231639
Principal investigator 1 Incyte Corporation $489.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231649
Principal investigator 1 Incyte Corporation $105.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231705
Principal investigator 1 Incyte Corporation $489.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231709
Principal investigator 1 Incyte Corporation $489.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231711
Principal investigator 1 Incyte Corporation $489.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231715
Principal investigator 1 Incyte Corporation $105.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231717
Principal investigator 1 Incyte Corporation $489.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231719
Principal investigator 1 Incyte Corporation $105.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231721
Principal investigator 1 Incyte Corporation $489.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231723
Principal investigator 1 Incyte Corporation $105.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231727
Principal investigator 1 BeiGene, Ltd. $40,382.40 03/08/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933753251
Principal investigator 1 Incyte Corporation $2,295.56 03/03/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231599
Principal investigator 1 Incyte Corporation $2,869.45 03/03/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231601
Principal investigator 1 Incyte Corporation $600.00 03/03/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231603
Principal investigator 1 Incyte Corporation $466.00 02/24/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231589
Principal investigator 1 Incyte Corporation $212.00 02/24/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231591
Principal investigator 1 Genentech, Inc. $1,500.00 02/23/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
CLL 1L FIT GV FCR BR No dispute reported 06/30/2026 950682735
Principal investigator 1 Celgene Corporation $5,751.00 02/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185185
Principal investigator 1 Celgene Corporation $714.00 02/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185245
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231467
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231473
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231653
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231655
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231657
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231663
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231665
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231667
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231669
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231671
Principal investigator 1 Incyte Corporation $105.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231677
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231679
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231681
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231683
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231685
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231687
Principal investigator 1 Incyte Corporation $489.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231691
Principal investigator 1 BeiGene, Ltd. $10,095.60 01/31/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 933753069
Principal investigator 1 Incyte Corporation $1,573.89 01/27/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231397
Principal investigator 1 Incyte Corporation $1,721.67 01/27/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231399
Principal investigator 1 Incyte Corporation $360.00 01/20/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231401
Principal investigator 1 Incyte Corporation $5,738.90 01/20/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231415
Principal investigator 1 Incyte Corporation $212.00 01/20/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231431
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,598.84 01/20/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 937162053
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,297.08 01/20/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 937162057
Principal investigator 1 Celgene Corporation $528.00 01/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185165
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231441
Principal investigator 1 Incyte Corporation $850.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231449
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231457
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231477
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231481
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231483
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231493
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231495
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231497
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231501
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231503
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231505
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231509
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231525
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231529
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231533
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231535
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231539
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231545
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231547
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231553
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231561
Principal investigator 1 Incyte Corporation $489.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231563
Principal investigator 1 Incyte Corporation $105.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 905231565
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 890235917
Principal investigator 1 Seagen Inc. $956.00 01/15/2022 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917930675
Principal investigator 1 Novartis Pharmaceuticals Corporation $319,548.55 01/11/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
A PHASE III, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF ORAL ASCIMINIB VERSUS INVESTIGATOR SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE No dispute reported 06/30/2026 909420193
Principal investigator 1 Novartis Pharmaceuticals Corporation $503.39 01/11/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY ALLISON CANCER
A PHASE III, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF ORAL ASCIMINIB VERSUS INVESTIGATOR SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE No dispute reported 06/30/2026 909420321
Principal investigator 1 Genentech, Inc. $1,500.00 01/10/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
CLL 1L FIT GV FCR BR No dispute reported 06/30/2026 950689789